Sinopharm Financial Statements From 2010 to 2025

X2S Stock  EUR 2.54  0.04  1.55%   
Sinopharm Group financial statements provide useful quarterly and yearly information to potential Sinopharm Group Co investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Sinopharm Group financial statements helps investors assess Sinopharm Group's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Sinopharm Group's valuation are summarized below:
Sinopharm Group Co does not presently have any fundamental trend indicators for analysis.
Check Sinopharm Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sinopharm Group's main balance sheet or income statement drivers, such as , as well as many indicators such as . Sinopharm financial statements analysis is a perfect complement when working with Sinopharm Group Valuation or Volatility modules.
  
This module can also supplement various Sinopharm Group Technical models . Check out the analysis of Sinopharm Group Correlation against competitors.

Sinopharm Group Co Company Total Asset Analysis

Sinopharm Group's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Total Asset

 = 

Tangible Assets

+

Intangible Assets

More About Total Asset | All Equity Analysis

Current Sinopharm Group Total Asset

    
  335.41 B  
Most of Sinopharm Group's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sinopharm Group Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
Competition

Based on the latest financial disclosure, Sinopharm Group Co has a Total Asset of 335.41 B. This is much higher than that of the Other sector and significantly higher than that of the Other industry. The total asset for all Germany stocks is notably lower than that of the firm.

Sinopharm Group Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Sinopharm Group's current stock value. Our valuation model uses many indicators to compare Sinopharm Group value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sinopharm Group competition to find correlations between indicators driving Sinopharm Group's intrinsic value. More Info.
Sinopharm Group Co is rated first in current valuation category among its peers. It is rated fourth in price to book category among its peers . The ratio of Current Valuation to Price To Book for Sinopharm Group Co is about  17,937,579,674 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sinopharm Group's earnings, one of the primary drivers of an investment's value.

About Sinopharm Group Financial Statements

Sinopharm Group shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Sinopharm Group investors may analyze each financial statement separately, they are all interrelated. The changes in Sinopharm Group's assets and liabilities, for example, are also reflected in the revenues and expenses on on Sinopharm Group's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Sinopharm Stock Analysis

When running Sinopharm Group's price analysis, check to measure Sinopharm Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sinopharm Group is operating at the current time. Most of Sinopharm Group's value examination focuses on studying past and present price action to predict the probability of Sinopharm Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sinopharm Group's price. Additionally, you may evaluate how the addition of Sinopharm Group to your portfolios can decrease your overall portfolio volatility.